Related Experiment Videos
Prostate-specific antigen in prostatic carcinoma.
C D Jurincic1, H U Pixberg, A Gasser
1Department of Urology, General Hospital Celle, FRG.
Urologia Internationalis
|January 1, 1990
Summary
Prostate-specific antigen (PSA) shows clinical value in detecting prostate cancer. A 10 ng/ml cutoff is recommended over 2.5 ng/ml for improved specificity and monitoring tumor growth.
Area of Science:
- Uro-oncology
- Clinical chemistry
Background:
- Prostate-specific antigen (PSA) is a biomarker used for prostate cancer detection and monitoring.
- Established cutoff values for PSA testing, like 2.5 ng/ml, have limitations in clinical practice.
Observation:
- Analysis of sera from patients with prostatic carcinoma, benign prostatic hypertrophy (BPH), and other urological diseases.
- PSA values ranged from 0.1 to 1,828.9 ng/ml, with 51% around 2.5 ng/ml and 76.8% around 10 ng/ml.
Findings:
- The commercial cutoff of 2.5 ng/ml resulted in 61% false positives in BPH patients, indicating low specificity.
- Using a 10 ng/ml cutoff reduced false negatives in prostate cancer patients to 14.6% compared to 9.75% at 2.5 ng/ml.
- PSA levels correlated with disease stage and showed a decline after therapeutic interventions.
Implications:
- A 10 ng/ml cutoff for PSA may offer a more clinically useful balance between sensitivity and specificity for prostate cancer detection.
- PSA serves as a valuable adjuvant marker for monitoring tumor growth and treatment response in patients with prostate cancer.